XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript

XOMA Royalty held its Q4 and full-year 2025 earnings call on March 18, 2026; management (CEO Owen Hughes, CIO Brad Sitko, CFO Jeff Trigilio) reviewed 2025 financial results and will discuss recent business development, portfolio updates and upcoming catalysts. A press release with the financial results was posted to the company's IR website and a replay will be available; no specific financial metrics or guidance are included in the provided excerpt. Management reiterated forward-looking statement cautions and referenced risk factors.

Analysis

Royalty owners (XOMA, peers) are the primary beneficiaries of a stable-to-improving cadence of royalty receipts, but they are secondarily exposed to capital markets and M&A flows: a buyer-friendly equity window or aggressive private purchasers can rerate royalty multiples higher quickly, while higher rates or a financing squeeze compresses valuations. The economics act like long-duration cash flows — think equity-like upside with bond-like duration — so competitors with deeper balance sheets or flexible monetization platforms (strategic buyers, private royalty funds) can arbitrage pricing dislocations by buying assets into weakness.

Key risks are macro-driven discount-rate moves and idiosyncratic clinical/patent outcomes for underlying drugs. Using a working duration of ~6–10 years implies a 100bp parallel move in discount rates could change PV by roughly 6–10% — that’s a meaningful mark-to-market swing in months, not years. Off-cycle catalysts that would reverse the trend include announced asset monetizations, unexpected royalty step-ups (e.g., accelerated sales or pricing) or the opposite: surprise generics/compulsory licenses that truncate revenue tails.

Tactically, the highest-leverage near-term plays are option structures and pairs that isolate idiosyncratic royalty execution from sector rate sensitivity. A long-dated call spread captures upside from deal activity and improving royalty growth while capping premium paid; a collar or protective puts hedge the rate/patent tail. Relative-value pairs (long smaller royalty owner / short larger, more rate-sensitive peer) monetize divergence if acquirers prefer nimble, higher-yielding targets.

Contrarian angle: the market currently pricing XOMA-like names as pure earnings streams underweights management optionality to monetize assets or transact accretively — if management pushes more active balance-sheet deployment (structured sales, buybacks), equity rerating is quick and non-linear. Conversely, if multiple clinical readouts cluster negatively, downside is likewise rapid — position sizing and convex hedges matter more than directional exposure.

Key Decisions for Investors

• Buy XOMA equity on >=10% intraday pullback from current levels, target 12–18 month hold; objective +25–40% upside if management executes monetizations or M&A occurs, stop-loss at -12%.
• Initiate a 12-month XOMA call spread (buy 1x long-dated ~25% OTM call, sell a higher ~60% OTM call) sized at 2–4% of portfolio capital — limited downside = premium paid (~100% loss of premium), potential 3–5x return if asset sales/M&A rerate occur.
• Establish a collar for existing XOMA position: buy 9–12 month puts ~15% OTM and sell 9–12 month calls ~25% OTM to fund protection. This preserves upside while capping drawdown from rate-driven repricing over the next 6–12 months.
• Pair trade: long XOMA / short RPRX (Royalty Pharma) sized dollar-neutral for 6–12 months to exploit idiosyncratic royalty monetization optionality vs larger peer’s higher rate sensitivity; target +10–20% relative performance, cut if spread moves >15% adverse.
• Allocate 1–2% of capital to catastrophe hedge: buy 6–9 month puts across the royalty space (index or basket if available) to protect against clustered negative clinical outcomes or sudden generic entry that could trigger >20% drawdowns.